94 related articles for article (PubMed ID: 20219270)
1. Synthesis and study of antiproliferative activity of novel thienopyrimidines on glioblastoma cells.
Pédeboscq S; Gravier D; Casadebaig F; Hou G; Gissot A; De Giorgi F; Ichas F; Cambar J; Pometan JP
Eur J Med Chem; 2010 Jun; 45(6):2473-9. PubMed ID: 20219270
[TBL] [Abstract][Full Text] [Related]
2. Receptor tyrosine kinase inhibitors and cytotoxic drugs affect pleural mesothelioma cell proliferation: insight into EGFR and ERK1/2 as antitumor targets.
Barbieri F; Würth R; Favoni RE; Pattarozzi A; Gatti M; Ratto A; Ferrari A; Bajetto A; Florio T
Biochem Pharmacol; 2011 Nov; 82(10):1467-77. PubMed ID: 21787763
[TBL] [Abstract][Full Text] [Related]
3. Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity.
Gangjee A; Zeng Y; Ihnat M; Warnke LA; Green DW; Kisliuk RL; Lin FT
Bioorg Med Chem; 2005 Sep; 13(18):5475-91. PubMed ID: 16039863
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of 2,7-diamino-thiazolo[4,5-d] pyrimidine analogues as anti-tumor epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.
Lin R; Johnson SG; Connolly PJ; Wetter SK; Binnun E; Hughes TV; Murray WV; Pandey NB; Moreno-Mazza SJ; Adams M; Fuentes-Pesquera AR; Middleton SA
Bioorg Med Chem Lett; 2009 Apr; 19(8):2333-7. PubMed ID: 19286381
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of pyrrolo[2,3-d]pyrimidine derivatives and their antiproliferative activity against melanoma cell line.
Jung MH; Kim H; Choi WK; El-Gamal MI; Park JH; Yoo KH; Sim TB; Lee SH; Baek D; Hah JM; Cho JH; Oh CH
Bioorg Med Chem Lett; 2009 Dec; 19(23):6538-43. PubMed ID: 19857963
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity study leading to identification of a highly active thienopyrimidine based EGFR inhibitor.
Bugge S; Kaspersen SJ; Larsen S; Nonstad U; Bjørkøy G; Sundby E; Hoff BH
Eur J Med Chem; 2014 Mar; 75():354-74. PubMed ID: 24556149
[TBL] [Abstract][Full Text] [Related]
7. Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors.
Rheault TR; Caferro TR; Dickerson SH; Donaldson KH; Gaul MD; Goetz AS; Mullin RJ; McDonald OB; Petrov KG; Rusnak DW; Shewchuk LM; Spehar GM; Truesdale AT; Vanderwall DE; Wood ER; Uehling DE
Bioorg Med Chem Lett; 2009 Feb; 19(3):817-20. PubMed ID: 19111461
[TBL] [Abstract][Full Text] [Related]
8. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of F90, an epidermal growth factor receptor tyrosine kinase inhibitor, on glioblastoma cell line SHG-44.
Liu FJ; Gui SB; Li CZ; Sun ZL; Zhang YZ
Chin Med J (Engl); 2008 Sep; 121(17):1702-6. PubMed ID: 19024103
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of proliferation, migration, and matrix metalloprotease production in malignant mesothelioma cells by tyrosine kinase inhibitors.
Liu Z; Klominek J
Neoplasia; 2004; 6(6):705-12. PubMed ID: 15720796
[TBL] [Abstract][Full Text] [Related]
11. Antiproliferative activity of new 1-aryl-4-amino-1H-pyrazolo[3,4-d]pyrimidine derivatives toward the human epidermoid carcinoma A431 cell line.
Schenone S; Bruno O; Bondavalli F; Ranise A; Mosti L; Menozzi G; Fossa P; Donnini S; Santoro A; Ziche M; Manetti F; Botta M
Eur J Med Chem; 2004 Nov; 39(11):939-46. PubMed ID: 15501543
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases.
Xu G; Searle LL; Hughes TV; Beck AK; Connolly PJ; Abad MC; Neeper MP; Struble GT; Springer BA; Emanuel SL; Gruninger RH; Pandey N; Adams M; Moreno-Mazza S; Fuentes-Pesquera AR; Middleton SA; Greenberger LM
Bioorg Med Chem Lett; 2008 Jun; 18(12):3495-9. PubMed ID: 18508264
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
[TBL] [Abstract][Full Text] [Related]
14. The synthesis and SAR of 2-amino-pyrrolo[2,3-d]pyrimidines: a new class of Aurora-A kinase inhibitors.
Moriarty KJ; Koblish HK; Garrabrant T; Maisuria J; Khalil E; Ali F; Petrounia IP; Crysler CS; Maroney AC; Johnson DL; Galemmo RA
Bioorg Med Chem Lett; 2006 Nov; 16(22):5778-83. PubMed ID: 16949284
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.
Smaill JB; Palmer BD; Rewcastle GW; Denny WA; McNamara DJ; Dobrusin EM; Bridges AJ; Zhou H; Showalter HD; Winters RT; Leopold WR; Fry DW; Nelson JM; Slintak V; Elliot WL; Roberts BJ; Vincent PW; Patmore SJ
J Med Chem; 1999 May; 42(10):1803-15. PubMed ID: 10346932
[TBL] [Abstract][Full Text] [Related]
16. 2-Thienyl-4-furyl-6-aryl pyridine derivatives: synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study.
Thapa P; Karki R; Thapa U; Jahng Y; Jung MJ; Nam JM; Na Y; Kwon Y; Lee ES
Bioorg Med Chem; 2010 Jan; 18(1):377-86. PubMed ID: 19939682
[TBL] [Abstract][Full Text] [Related]
17. Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.
Johnson FM; Saigal B; Donato NJ
J Cell Physiol; 2005 Nov; 205(2):218-27. PubMed ID: 15887238
[TBL] [Abstract][Full Text] [Related]
18. Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling.
Weigel MT; Meinhold-Heerlein I; Bauerschlag DO; Schem C; Bauer M; Jonat W; Maass N; Mundhenke C
Cancer Lett; 2009 Jan; 273(1):70-9. PubMed ID: 18809244
[TBL] [Abstract][Full Text] [Related]
19. Novel N2-substituted pyrazolo[3,4-d]pyrimidine adenosine A3 receptor antagonists: inhibition of A3-mediated human glioblastoma cell proliferation.
Taliani S; La Motta C; Mugnaini L; Simorini F; Salerno S; Marini AM; Da Settimo F; Cosconati S; Cosimelli B; Greco G; Limongelli V; Marinelli L; Novellino E; Ciampi O; Daniele S; Trincavelli ML; Martini C
J Med Chem; 2010 May; 53(10):3954-63. PubMed ID: 20408530
[TBL] [Abstract][Full Text] [Related]
20. Novel heterocyclic-fused pyrimidine derivatives: synthesis, molecular modeling and pharmacological screening.
Arafa RK; Nour MS; El-Sayed NA
Eur J Med Chem; 2013 Nov; 69():498-507. PubMed ID: 24090920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]